FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity

DUBLIN, June 21, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company ' s supplemental biologics application (sBLA) for Botox for the treatment of pediatric patients (2 to...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news